| 2025-07-18 |
复牌提示：
2025-07-17 19:50:00 停牌，复牌日期 2025-07-21
|
| 2025-07-17 |
详情>>
内部人交易：
Albers Jeffrey W.等共交易45笔
|
| 2025-05-01 |
详情>>
股本变动：
变动后总股本6458.22万股
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益0.01美元,归母净利润49.60万美元,同比去年增长-99.44%
|
| 2025-05-01 |
财报披露：
美东时间 2025-05-01 盘前发布财报
|
| 2025-04-24 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.Election of the three Class I directors named herein to our board of directors, each to serve for a three-year term, or until their successor has been duly elected and qualified.
2.Approve a non-binding advisory vote on the compensation paid to our named executive officers.
3.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
|
| 2025-02-13 |
详情>>
业绩披露：
2022年年报每股收益-9.35美元,归母净利润-5.58亿美元,同比去年增长13.44%
|
| 2025-02-13 |
详情>>
业绩披露：
2024年年报每股收益-1.07美元,归母净利润-6708.9万美元,同比去年增长86.77%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.27美元,归母净利润-1713.3万美元,同比去年增长95.67%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益0.63美元,归母净利润3914.10万美元,同比去年增长114.92%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益1.45美元,归母净利润8913.60万美元,同比去年增长168.80%
|
| 2024-04-25 |
股东大会：
将于2024-06-12召开股东大会
会议内容 ▼▲
- 1.Election of the three Class III directors named herein to our board of directors, each to serve for a three-year term, or until their successor has been duly elected and qualified
2.Approve a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers
3.Approve a non-binding advisory vote on the compensation paid to our named executive officers
4.Approve the Blueprint Medicines Corporation 2024 Stock Incentive Plan
5.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024
|
| 2024-02-15 |
详情>>
业绩披露：
2023年年报每股收益-8.37美元,归母净利润-5.07亿美元,同比去年增长9.06%
|
| 2024-02-15 |
详情>>
业绩披露：
2021年年报每股收益-11.01美元,归母净利润-6.44亿美元,同比去年增长-305.2%
|
| 2023-10-26 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-6.55美元,归母净利润-3.96亿美元,同比去年增长0.70%
|
| 2023-08-02 |
详情>>
业绩披露：
2023年中报每股收益-4.35美元,归母净利润-2.62亿美元,同比去年增长1.26%
|
| 2023-05-04 |
详情>>
业绩披露：
2023年一季报每股收益-2.15美元,归母净利润-1.3亿美元,同比去年增长-22.23%
|
| 2023-04-28 |
股东大会：
将于2023-06-21召开股东大会
会议内容 ▼▲
- 1.Election of three Class II directors nominated by our board of directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders, or until their successor has been duly elected and qualified
2.Approve a non-binding, advisory vote on the compensation paid to our named executive officers
3.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023
|
| 2022-04-29 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors nominated by our board of directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders or until his or her successor has been duly elected and qualified;
2.To approve a non-binding, advisory vote on the compensation paid to our named executive officers;
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-21 |
股东大会：
将于2021-06-02召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2024 annual meeting of stockholders or until his or her successor has been duly elected and qualified;
2.To approve a non-binding, advisory vote on the compensation paid to our named executive officers;
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2020-04-29 |
股东大会：
将于2020-06-23召开股东大会
会议内容 ▼▲
- 1.The election of three Class II directors nominated by our board of directors, each to serve for a three-year term expiring at the 2023 annual meeting of stockholders or until his or her successor has been duly elected and qualified;
2.To approve a non-binding, advisory vote on the compensation paid to our named executive officers;
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2019-04-29 |
股东大会：
将于2019-06-18召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors nominated by our board of directors, each to serve for a three-year term expiring at the 2022 annual meeting of stockholders or until his or her successor has been duly elected and qualified;
2.To approve a non-binding, advisory vote on the compensation paid to our named executive officers;
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2019; 4.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.The election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2021 annual meeting of stockholders or until his or her successor has been duly elected and qualified;
2.To approve an advisory vote on the compensation paid to our named executive officers;
3.To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers;
4.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2018;
5.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1. The election of three Class II directors nominated by our board of directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders or until his successor has been duly elected and qualified;
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2017;
3. The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-21召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors nominated by our board of directors, each to serve for a three-year term expiring at the 2019 annual meeting of stockholders or until his successor has been duly elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016; 3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|